The ligands of PD-1, PD-L1, and PD-L2, which are expressed on both tumor and normal cells within the tumor microenvironment (55–57, 60), are also interesting targets for immunotherapy (Figure 4). The gene discussed is PDCD1; the disease is neoplasm.